Prithvi Tummala

Background:  Diffuse midline glioma (DMG) is a universally fatal pediatric brain cancer of the brainstem, thalamus, and spinal cord, with a median survival of 11 to 13 months and no effective therapy in over 30 years.^1,2 A defining oncogenic driver is the H3K27M histone mutation, which inhibits PRC2-mediated trimethylation of H3K27, causing epigenetic dysregulation and arresting tumor cells in an oligodendrocyte precursor cell (OPC)-like progenitor state.^1,4 While glutamatergic neuron-to-glioma synapses are established growth drivers in glioma broadly, the role of GABAergic signaling in DMG remained unexplored, representing a critical gap in understanding this tumor’s biology.^2,3

Research Objectives:  This narrative review examined how H3K27M-mutated DMGs exploit NKCC1-driven excitatory GABAergic signaling as a subtype-specific growth mechanism and assessed the translational implications for therapy.

Methods:  PubMed was searched from 2018 to 2025 using the MeSH terms and keywords: “diffuse midline glioma,” “diffuse intrinsic pontine glioma,” “H3K27M,” “NKCC1,” “SLC12A2,” “GABAergic signaling,” “neuron-glioma synapse,” “bumetanide,” “oligodendrocyte precursor cell,” “TrkB,” and “malignant synaptic potentiation.” Eight primary research articles were selected based on mechanistic relevance to DMG neurobiology and therapeutic targeting.

Results:  Functional GABAergic neuron-to-DMG synapses were confirmed by patch-clamp electrophysiology, which identified postsynaptic currents abolished by the GABA_A antagonist bicuculline, and further validated by optogenetic stimulation of channelrhodopsin-expressing GABAergic neurons, which produced time-locked depolarization in tumor cells.¹ Rather than silencing DMG cells as expected, this GABAergic input was excitatory. A genetically encoded chloride sensor revealed markedly elevated intracellular chloride in DMG cells, reversing the GABA_A electrochemical gradient and causing net chloride efflux and membrane depolarization.¹ Immunofluorescence and RNA sequencing traced this reversal to high NKCC1 (SLC12A2) expression, a pattern absent in pediatric and adult glioblastoma, establishing excitatory GABAergic signaling as a DMG-specific vulnerability.¹ Single-cell RNA sequencing of patient tumor samples provided the mechanistic basis: DMG cells predominantly resemble OPCs, which physiologically overexpress NKCC1 during a progenitor window, and H3K27M-mediated PRC2 inhibition permanently arrests cells in this state, locking in NKCC1 overexpression across the tumor.⁴ The functional consequence was confirmed in xenograft mouse models tracked by bioluminescence imaging: bumetanide, an FDA-approved NKCC1 inhibitor with an established pediatric safety profile, significantly reduced tumor growth, while lorazepam, a GABA_A potentiator, significantly accelerated it.¹ Beyond the GABAergic axis, neuronal activity-dependent BDNF was shown to activate TrkB and CaMKII in glioma cells, driving GluA2 AMPA receptor insertion into the tumor membrane and potentiating glutamatergic synaptic input, a process termed malignant synaptic potentiation.⁵ TrkB knockout and CaMKII inhibition each reduced tumor growth and improved survival in mouse models, identifying a second, independently targetable growth axis.⁵

Conclusion:  H3K27M-mutated DMGs co-opt two neurotransmitter axes for proliferation: NKCC1-sustained elevated intracellular chloride renders GABAergic input excitatory, while BDNF-TrkB-CaMKII signaling amplifies glutamatergic drive.^1,5 Bumetanide offers a mechanistically grounded, clinically feasible near-term intervention given its existing pediatric approval, and lorazepam’s tumor-accelerating effect demands immediate reassessment of benzodiazepine use in this population.¹ Dual targeting of NKCC1 and TrkB represents a rational combination strategy for a disease with no effective treatment.^1,5

Work Cited:

1. Barron T, Yalcin B, Su M, et al. GABAergic neuron-to-glioma synapses in diffuse midline gliomas. Nature. 2025;638(8049):136-145.
2. Aldape K, Brindle KM, Chesler L, et al. Challenges to curing primary brain tumours. Nat Rev Clin Oncol. 2019;16(5):309-320.
3. Venkataramani V, Tanev DI, Strahle C, et al. Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature. 2019;573(7775):532-538.
4. Filbin MG, Tirosh I, Hovestadt V, et al. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science. 2018;360(6386):331-335.
5. Taylor KR, Barron T, Hui A, et al. Glioma synapses recruit mechanisms of adaptive plasticity. Nature. 2023;623(7988):366-374.
6. Venkatesh HS, Morishita W, Bhatt DL, et al. Electrical and synaptic integration of glioma into neural circuits. Nature. 2019;573(7775):539-545.
7. Gianno F, Giovannoni I, Cafferata B, et al. Paediatric-type diffuse high-grade gliomas in the 5th CNS WHO Classification. Pathologica. 2022;114(6):422-435.
8. Venkataramani V, Yang Y, Ille S, et al. Cancer Neuroscience of Brain Tumors. Cancer Discov. 2025;15(1):39-51.